AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01993615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Surgery
Description: The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
Study NCT01993615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
Study NCT00377182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048 3000mg
Description: 3000mg po bid for 4 weeks
Study NCT01661569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headspace On-the-go app
Description: Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
Study NCT03427632 — intervention group
Intervention type: DRUG
Intervention: Bone Cements
Description: patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
Study NCT00681603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)
Description: subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
Study NCT01022970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX576
Study NCT02570646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QA-DDS
Description: QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
Study NCT01565590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.2-1.5 mcg/kg/hr
Study NCT01565590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 5-80 mcg/kg/min
Study NCT03173612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
Study NCT02485587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Arousal-Biofeedback
Description: biofeedback of biological measures of arousal (electrodermal activity)
Study NCT02485587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: counseling, psychoeducation
Study NCT06073197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
Study NCT03171311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic guided PCI
Description: Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
Study NCT03171311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT guided PCI
Description: OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
Study NCT06073197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined deep and superficial serratus anterior plane block
Description: Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
Study NCT04545099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Administration of Sugammadex for muscle relaxation reversal
Study NCT04545099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Administration of Neostigmine for muscle relaxation reversal
Study NCT03467295 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
Study NCT03467295 — intervention group
Intervention type: PROCEDURE
Intervention: Observation
Description: Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
Study NCT01419015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN XT NovaFlex delivery system
Description: Transcatheter aortic valve implantation via transfemoral approach.
Study NCT03289741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
Study NCT03289741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAR Lanreotide
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
Study NCT03289741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
Study NCT00180271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillation
Description: Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
Study NCT00180271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
Study NCT02990455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced nicotine cigarettes
Description: Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
Study NCT01887106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 single ascending doses, oral suspension
Description: Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
Study NCT01887106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single ascending doses, oral suspension
Description: Single dose, oral suspension matching placebo
Study NCT01887106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
Study NCT01887106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension matching placebo
Study NCT00538746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP
Study NCT00538746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV
Study NCT03821883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo qd
Study NCT00454883 — intervention group
Intervention type: DRUG
Intervention: ziprasidone
Description: Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
Study NCT00921726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
Study NCT01061177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
Study NCT01180985 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: silicone hydrogel contact lens
Study NCT01180985 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: comfilcon A
Description: silicone hydrogel contact lens
Study NCT02051504 — intervention group
Intervention type: BEHAVIORAL
Intervention: Incremental maximal exercise
Description: The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
Study NCT02051504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Glucose Tolerance Test
Description: The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
Study NCT02051504 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
Study NCT02051504 — intervention group
Intervention type: PROCEDURE
Intervention: Combined DLCO-DLNO
Description: Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
Study NCT02051504 — intervention group
Intervention type: PROCEDURE
Intervention: Dual energy X-ray absorptiometry
Description: Body composition is measured using dual energy X-ray absorptiometry at rest.
Study NCT01796067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Family Weight Loss
Description: This group will receive the comprehensive motivational and family weight loss intervention.
Study NCT01796067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Health Education
Description: This group will receive the comprehensive basic health education intervention.
Study NCT01796067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Health Education
Description: This group will receive the comprehensive basic health education intervention.
Study NCT01796067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention
Description: Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
Study NCT01796067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Control
Description: Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
Study NCT01796067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Control
Description: Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
Study NCT04565119 — intervention group
Intervention type: OTHER
Intervention: No intervention. This is an observational study.
Description: There are no interventions being tested in the Bio-BOOST study.
Study NCT04593056 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference
Study NCT04593056 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban dispensing claim is used as the exposure
Study NCT04065958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-mindfulness
Description: Body-mind therapy
Study NCT04065958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education and physiotherapy
Description: Lectures and physiotherapy
Study NCT00538746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV + CPAP
Study NCT02663479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiopressin
Study NCT02663479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02394795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT02394795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT02581618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
Study NCT02307656 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Study NCT02307656 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cobicistat
Study NCT02307656 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Active Pharmaceutical Ingredient
Study NCT02168296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient added to starchy meal
Study NCT02168296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient added to liquid
Study NCT02168296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Plant-based ingredient
Study NCT01492296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy after short fasting
Description: patients were evaluated with endoscopy after fasting for two hours
Study NCT01492296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional fasting
Description: patients were evaluated after fasting for 8 hours
Study NCT01572818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebotomy
Description: 7 ml/kg without exceeding 500 mL
Study NCT01572818 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary and lifestyle counseling
Description: dietary and lifestyle counseling
Study NCT01572818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary and lifestyle counseling
Description: dietary and lifestyle counseling
Study NCT02203669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
Study NCT02203669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured In-Office Therapy
Description: Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
Study NCT04209205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 3 mg/kg
Description: AIN457 3 mg/kg delivered by i.v. infusion
Study NCT03865459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
Study NCT02267226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octafibrin
Study NCT03441347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific rehabilitation program
Description: 17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
Study NCT03441347 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Specific rehabilitation program
Description: 17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
Study NCT03441347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants will receive their usual care for 17 weeks, which may vary for each individual
Study NCT03742115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 twice weekly for 2 weeks and then weekly
Study NCT03742115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
Study NCT03742115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
Study NCT03742115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 weekly
Study NCT03742115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: 0.5 g/kg, once every 4 weeks
Study NCT03250156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT with proctored practice
Description: The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
Study NCT03250156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBAT with non-proctored practice
Description: The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
Study NCT01300364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reboxetine
Description: 8mg/day.